Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching

Epigenetics and Chromatin

Volumn 7, Issue 1, 2014, Pages

  Philpott, Martin ^a,d   Rogers, Catherine M ^a   Yapp, Clarence ^a   Wells, Chris ^a,e   Lambert, Jean Philippe ^b   Strain Damerell, Claire ^a   Burgess Brown, Nicola A ^a   Gingras, Anne Claude ^b,c   Knapp, Stefan ^a   Müller, Susanne ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bromodomain; Cell based assay; Confocal microscopy; Epigenetics; Fluorescence recovery after photobleaching; Histone acetylation; Small molecule inhibitor

Indexed keywords

EID: 84904082319     PISSN: None     EISSN: 17568935     Source Type: Journal    
DOI: 10.1186/1756-8935-7-14     Document Type: Article

References (59)

1. Histone recognition and large-scale structural analysis of the human bromodomain family. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Müller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S, Cell 2012 149 214 231
2. Bromodomains and their pharmacological inhibitors. Gallenkamp D, Gelato KA, Haendler B, Weinmann H, ChemMedChem 2014 9 438 464
3. Bromodomains as therapeutic targets. Muller S, Filippakopoulos P, Knapp S, Expert Rev Mol Med 2011 13 29
4. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z, Hobisch A, J Pathol 2004 204 159 166 (Pubitemid 39335289)
5. Androgen deprivation increases p300 expression in prostate cancer cells. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ, Cancer Res 2007 67 3422 3430 (Pubitemid 46724883)
6. Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y, Deng A, Chen J, Wang G, Zhu S, Kang J, J Biol Chem 2013 288 14510 14521
7. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, Kutok JL, Toretsky JA, Tadavarthy AK, Kees UR, Fletcher JA, Aster JC, Oncogene 2008 27 2237 2242 (Pubitemid 351483375)
8. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Panagopoulos I, Fioretos T, Isaksson M, Samuelsson U, Billström R, Strömbeck B, Mitelman F, Johansson B, Hum Mol Genet 2001 10 395 404 (Pubitemid 32166550)
9. A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma. Constellation Pharmaceuticals; Leukemia and Lymphoma Society, ClinicalTrials.gov Identifier: NCT01949883 [ http://clinicaltrials.gov/ct2/show/NCT01949883 (last updated 27 March 2014)
10. A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers. GlaxoSmithKline, ClinicalTrials.gov Identifier: NCT01587703 [ http://www.clinicaltrials.gov/ct2/show/NCT01587703 (last updated 22 May 2014)
11. A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies. GlaxoSmithKline, ClinicalTrials.gov Identifier: NCT01943851 [ http://clinicaltrials.gov/ct2/show/NCT01943851 (last updated 22 May 2014)
12. A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015 in Haematological Malignancies. OncoEthix, ClinicalTrials.gov Identifier: NCT01713582 [ http://clinicaltrials.gov/ct2/show/NCT01713582 (last updated 29 March 2014)
13. A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously. Tensha Therapeutics, ClinicalTrials.gov Identifier: NCT01987362 [ http://clinicaltrials.gov/ct2/show/NCT01987362 (last updated 17 December 2013)
14. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Philpott M, Yang J, Tumber T, Fedorov O, Uttarkar S, Filippakopoulos P, Picaud S, Keates T, Felletar I, Ciulli A, Knapp S, Heightman TD, Mol Biosyst 2011 7 2899 2908
15. Analysis of protein and lipid dynamics using confocal fluorescence recovery after photobleaching (FRAP). Day CA, Kraft LJ, Kang M, Kenworthy AK, Curr Protoc Cytom 2012 62 2.19.1 2.19.29
16. FRAP analysis of binding: proper and fitting. Sprague BL, McNally JG, Trends Cell Biol 2005 15 84 91 (Pubitemid 40188218)
17. Selective inhibition of BET bromodomains. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE, Nature 2010 468 1067 1073
18. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O'Sullivan B, Müller S, Schwaller J, Stankovic T, Knapp S, Cancer Res 2013 73 3336 3346
19. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Dey A, Nishiyama A, Karpova T, McNally J, Ozato K, Mol Biol Cell 2009 20 4899 4909
20. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K, Mol Cell 2005 19 523 534 (Pubitemid 41140009)
21. 2-to-M transition. Dey A, Ellenberg J, Farina A, Coleman AE, Maruyama T, Sciortino S, Lippincott-Schwartz J, Ozato K, Mol Cell Biol 2000 20 6537 6549 (Pubitemid 30650239)
22. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Gamsjaeger R, Webb SR, Lamonica JM, Billin A, Blobel GA, Mackay JP, Mol Cell Biol 2011 31 2632 2640
23. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Lamonica JM, Deng W, Kadauke S, Campbell AE, Gamsjaeger R, Wang H, Cheng Y, Billin AN, Hardison RC, Mackay JP, Blobel GA, Proc Natl Acad Sci U S A 2011 108 159 E168
24. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S, Marsden B, Nocka K, Owen DR, Philpott M, Picaud S, Primiano MJ, Ralph MJ, Sciammetta N, Trzupek JD, J Med Chem 2012 55 9831 9837
25. TRIM involvement in transcriptional regulation. Cammas F, Khetchoumian K, Chambon P, Losson R, Adv Exp Med Biol 2012 770 59 76
26. TRIM24 links a non-canonical histone signature to breast cancer. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, Barton MC, Nature 2010 468 927 932
27. Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Flaus A, Martin DMA, Barton GJ, Owen-Hughes T, Nucleic Acids Res 2006 34 2887 2905 (Pubitemid 44540417)
28. A human protein atlas for normal and cancer tissues based on antibody proteomics. Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergström K, Brumer H, Cerjan D, Ekström M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Björklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, et al. Mol Cell Proteomics 2005 4 1920 1932 (Pubitemid 41830186)
29. PFI-3: selective chemical probe for SMARCA bromodomains. Structural Genomics Consortium (SGC), [ http://www.thesgc.org/chemical-probes/PFI-3 (accessed 28 June 2014)
30. The PHD finger/bromodomain of NoRC interacts with acetylated histone H4K16 and is sufficient for rDNA silencing. Zhou Y, Grummt I, Curr Biol 2005 15 1434 1438 (Pubitemid 41097550)
31. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Burrows AE, Smogorzewska A, Elledge SJ, Proc Natl Acad Sci U S A 2010 107 14280 14285
32. Gene regulation and tumor suppression by the bromodomain-containing protein BRD7. Mantovani F, Drost J, Voorhoeve PM, Del Sal G, Agami R, Cell Cycle 2010 9 2777 2781
33. Malignant genome reprogramming by ATAD2. Boussouar F, Jamshidikia M, Morozumi Y, Rousseaux S, Khochbin S, Biochim Biophys Acta 1829 2013 1010 1014
34. GCN5: a supervisor in all-inclusive control of vertebrate cell cycle progression through transcription regulation of various cell cycle-related genes. Kikuchi H, Takami Y, Nakayama T, Gene 2005 347 83 97 (Pubitemid 40348703)
35. New insights into BS69 functions. Velasco G, Grkovic S, Ansieau S, J Biol Chem 2006 281 16546 16550
36. ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression. Wen H, Li Y, Xi Y, Jiang S, Stratton S, Peng D, Tanaka K, Ren Y, Xia Z, Wu J, Li B, Barton MC, Li W, Li H, Shi X, Nature 2014 508 263 268
37. GSK2801: a selective chemical probe for BAZ2B/A bromodomains. Structural Genomics Consortium (SGC), [ http://www.thesgc.org/chemical-probes/GSK2801 (accessed 28 June 2014)
38. Bromosporine. Structural Genomics Consortium (SGC), [ http://www.thesgc.org/chemical-probes/bromosporine (accessed 28 June 2014)
39. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. Mishima Y, Miyagi S, Saraya A, Negishi M, Endoh M, Endo TA, Toyoda T, Shinga J, Katsumoto T, Chiba T, Yamaguchi N, Kitabayashi I, Koseki H, Iwama A, Blood 2011 118 2443 2453
40. Towards a knowledge-based Human Protein Atlas. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F, Nat Biotechnol 2010 28 1248 1250
41. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E, Suto RK, Wong NC, Wagner GS, Hansen HC, Young PR, PLoS One 2013 8 83190
42. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Müller S, Brennan PE, Knapp S, Filippakopoulos P, Proc Natl Acad Sci U S A 2013 110 19754 19759
43. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Janknecht R, Histol Histopathol 2002 17 657 668 (Pubitemid 34411218)
44. Genomic occupancy of the transcriptional co-activators p300 and CBP. Holmqvist PH, Mannervik M, Transcription 2013 4 18 23
45. CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. De Guzman RN, Wojciak JM, Martinez-Yamout MA, Dyson HJ, Wright PE, Biochemistry 2005 44 490 497 (Pubitemid 40105479)
46. ZZ domain of CBP: an unusual zinc finger fold in a protein interaction module. Legge GB, Martinez-Yamout MA, Hambly DM, Trinh T, Lee BM, Dyson HJ, Wright PE, J Mol Biol 2004 343 1081 1093 (Pubitemid 39345966)
47. A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies. Lin CH, Hare BJ, Wagner G, Harrison SC, Maniatis T, Fraenkel E, Mol Cell 2001 8 581 590 (Pubitemid 32946935)
48. Structural analyses of CREB-CBP transcriptional activator-coactivator complexes by NMR spectroscopy: implications for mapping the boundaries of structural domains. Radhakrishnan I, Pérez-Alvarado GC, Parker D, Dyson HJ, Montminy MR, Wright PE, J Mol Biol 1999 287 859 865 (Pubitemid 29188873)
49. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, Cole PA, Nature 2008 451 846 850 (Pubitemid 351253165)
50. I-CBP112-a CREBBP/EP300-selective chemical probe. Structural Genomics Consortium (SGC), [ http://www.thesgc.org/chemical-probes/ICBP112 (accessed 28 June 2014)
51. BR140, a novel zinc-finger protein with homology to the TAF250 subunit of TFIID. Thompson KA, Wang B, Argraves WS, Giancotti FG, Schranck DP, Ruoslahti E, Biochem Biophys Res Commun 1994 198 1143 1152
52. Mouse BAZ1A (ACF1) is dispensable for double-strand break repair but is essential for averting improper gene expression during spermatogenesis. Dowdle JA, Mehta M, Kass EM, Vuong BQ, Inagaki A, Egli D, Jasin M, Keeney S, PLoS Genet 2013 9 1003945
53. Exploration of human ORFeome: high-throughput preparation of ORF clones and efficient characterization of their protein products. Nagase T, Yamakawa H, Tadokoro S, Nakajima D, Inoue S, Yamaguchi K, Itokawa Y, Kikuno RF, Koga H, Ohara O, DNA Res 2008 15 137 149
54. Human ORFeome version 1.1: a platform for reverse proteomics. Rual JF, Hirozane-Kishikawa T, Hao T, Bertin N, Li S, Dricot A, Li N, Rosenberg J, Lamesch P, Vidalain PO, Clingingsmith TR, Hartley JL, Esposito D, Cheo D, Moore T, Simmons B, Sequerra R, Bosak S, Doucette-Stamm L, Le Peuch C, Vandenhaute J, Cusick ME, Albala JS, Hill DE, Vidal M, Genome Res 2004 14 2128 2135 (Pubitemid 39440195)
55. Label-free quantitative proteomics and SAINT analysis enable interactome mapping for the human Ser/Thr protein phosphatase 5. Skarra DV, Goudreault M, Choi H, Mullin M, Nesvizhskii AI, Gingras AC, Honkanen RE, Proteomics 2011 11 1508 1516
56. Site-directed mutagenesis by double polymerase chain reaction. Barik S, Methods Mol Biol 1993 15 277 286
57. Evidence for high specificity and efficiency of multiple recombination signals in mixed DNA cloning by the Multisite Gateway system. Sasaki Y, Sone T, Yoshida S, Yahata K, Hotta J, Chesnut JD, Honda T, Imamoto F, J Biotechnol 2004 107 233 243 (Pubitemid 38091753)
58. Measurement of dynamic protein binding to chromatin in vivo, using photobleaching microscopy. Phair RD, Gorski SA, Misteli T, Methods Enzymol 2004 375 393 414 (Pubitemid 38124881)
59. Ellison SLR, Barwick VJ, Duguid Farrant TJ, Practical Statistics for the Analytical Scientist: A Bench Guide Cambridge, UK: Royal Society of Chemistry 2 2009